Ad Header



The Pulse of the Pharmaceutical Industry

Roche’s hemophilia drug Hemlibra wins EU approval

Written by: | | Dated: Tuesday, February 27th, 2018


Roche says hemophilia drug Hemlibra wins EU approval


Swiss group Roche said on Tuesday the European Commission has approved its drug Hemlibra for people with hemophilia A who have developed resistance to standard treatments.

The approval was expected after a panel recommended it last month. The drug was already approved in the United States last year.

Hemlibra is among the new medicines that the Basel-based pharmaceuticals maker hopes will offset falling sales of its three biggest drugs, Rituxan, Avastin and Herceptin. Some analysts expect peak Hemlibra sales of more than $4 billion a year.

(Reporting by Silke Koltrowitz, Editing by Michael Shields)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation